These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 16845534

  • 1. Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
    Gillatt D.
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S17-26. PubMed ID: 16845534
    [Abstract] [Full Text] [Related]

  • 2. What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?
    Mason M.
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S27-35. PubMed ID: 16896883
    [Abstract] [Full Text] [Related]

  • 3. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
    Migliari R, Muscas G, Murru M, Verdacchi T, De Benedetto G, De Angelis M.
    Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
    [Abstract] [Full Text] [Related]

  • 4. The role of antiandrogen monotherapy in the treatment of prostate cancer.
    Anderson J.
    BJU Int; 2003 Mar; 91(5):455-61. PubMed ID: 12603397
    [Abstract] [Full Text] [Related]

  • 5. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
    Mahler C, Verhelst J, Denis L.
    Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
    [Abstract] [Full Text] [Related]

  • 6. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.
    Cochrane Database Syst Rev; 2014 Jun 30; 2014(6):CD009266. PubMed ID: 24979481
    [Abstract] [Full Text] [Related]

  • 7. Safety of antiandrogen therapy for treating prostate cancer.
    Ricci F, Buzzatti G, Rubagotti A, Boccardo F.
    Expert Opin Drug Saf; 2014 Nov 30; 13(11):1483-99. PubMed ID: 25270521
    [Abstract] [Full Text] [Related]

  • 8. Nilutamide: an antiandrogen for the treatment of prostate cancer.
    Dole EJ, Holdsworth MT.
    Ann Pharmacother; 1997 Jan 30; 31(1):65-75. PubMed ID: 8997470
    [Abstract] [Full Text] [Related]

  • 9. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
    Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.
    BJU Int; 2015 Jul 30; 116(1):30-6. PubMed ID: 25523493
    [Abstract] [Full Text] [Related]

  • 10. Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy?
    Abrahamsson PA.
    Eur Urol; 2001 Jul 30; 39 Suppl 1():22-8. PubMed ID: 11114597
    [Abstract] [Full Text] [Related]

  • 11. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
    Boccon-Gibod L.
    Eur Urol; 1998 Jul 30; 33(2):159-64. PubMed ID: 9519357
    [Abstract] [Full Text] [Related]

  • 12. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
    Sciarra A, Cardi A, Di Silverio F.
    Urol Int; 2004 Jul 30; 72(2):91-8. PubMed ID: 14963347
    [Abstract] [Full Text] [Related]

  • 13. Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.
    McLeod DG.
    Oncologist; 1997 Jul 30; 2(1):18-27. PubMed ID: 10388026
    [Abstract] [Full Text] [Related]

  • 14. Antiandrogens in the treatment of prostate cancer.
    Wirth MP, Hakenberg OW, Froehner M.
    Eur Urol; 2007 Feb 30; 51(2):306-13; discussion 314. PubMed ID: 17007995
    [Abstract] [Full Text] [Related]

  • 15. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
    Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G.
    Eur Urol; 1998 Feb 30; 33(5):447-56. PubMed ID: 9643663
    [Abstract] [Full Text] [Related]

  • 16. Antiandrogens as monotherapy for prostate cancer.
    Schröder FH.
    Eur Urol; 1998 Feb 30; 34 Suppl 3():12-7. PubMed ID: 9854190
    [Abstract] [Full Text] [Related]

  • 17. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
    Kolvenbag GJ, Iversen P, Newling DW.
    Urology; 2001 Aug 30; 58(2 Suppl 1):16-23. PubMed ID: 11502439
    [Abstract] [Full Text] [Related]

  • 18. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
    Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.
    J Urol; 2018 Nov 30; 200(5):956-966. PubMed ID: 29730201
    [Abstract] [Full Text] [Related]

  • 19. Antiandrogen monotherapy: indications and results.
    Iversen P.
    Urology; 2002 Sep 30; 60(3 Suppl 1):64-71. PubMed ID: 12231053
    [Abstract] [Full Text] [Related]

  • 20. Antiandrogen monotherapy in the management of advanced prostate cancer.
    Kaisary AV.
    Eur Urol; 1997 Sep 30; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.